"Amgen will be to market before OncoSec, with its treatment for the unmet needs of those that suffer from melanoma. However, OncoSec has the ability to supersede the TVEC approach, based on clinical results superiority. Both companies offer investors tremendous growth opportunity."
Thanks for the info! I have been in and out of INO a couple of times. I loaded up again after having read your message.
Motley Fool health-care analyst David Williamson discusses Zoegenix's (NASDAQ: ZGNX ) 30% leap, as the FDA delays approval for its pain medication Zohydro. A delay would make very little sense if the FDA were planning to reject the drug...
I don't think anything has changed, but the FDA may consider the drug does work better than the existing ones (24h vs 12 h, etc.).
FDA delay on Zogenix treatment could be positive, says Wells Fargo
Wells Fargo believes that the FDA's decision to delay its decision on Zogenix's Zohydro ERs, likely for a few weeks, could be a positive sign for the company. The fact that the FDA did not issue a complete response letter or issue a three month delay suggests that it could approve the drug, according to the firm. The firm thinks the stock's risk/reward profile is positive, and it maintains an Outperform rating on the shares.
Inside buying is still important for me. There is still a possibility the drug will be approved on March 1 because it works better than the existing ones.